Headquartered in Reinach, Switzerland, the company operates a highly. In recent years AGTC has entered into strategic partnerships with companies including Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, and Bionic Sight, LLC, an innovator in the emerging field of optogenetics and retinal coding. Archroma is a global, diversified provider of specialty chemicals serving the. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders. Its preclinical programs build on the Company’s industry leading AAV manufacturing technology and scientific expertise.

AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM B3 and ACHM A3).

AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. Bioptic driving is a method of driving that uses a patient's general vision and intermittent spotting through a small telescopic system that improves the sharpness of the patient's vision.ĪGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. These filters are often essential to bioptic driving. There is no specific treatment for ACHM, although deep red tinted glasses or contact lenses can reduce symptoms of light sensitivity and daytime blindness. ACHM is associated with extremely poor visual acuity, extreme light sensitivity resulting in daytime blindness, and complete loss of color discrimination. No Roadblocks is a program that funds tinted glasses or contact lenses, as well as bioptics, for individuals living with achromatopsia (ACHM), an inherited condition caused by mutations in one of several genes, with the two most common being mutations in either the CNGB3 or CNGA3 genes. 19, 2021 (GLOBE NEWSWIRE) - Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced it will be a sponsor of the Achroma Corp program, No Roadblocks. GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug.

Program helps those living with Achromatopsia receive filtered glasses and contact lenses to qualify for bioptic driving.

Achroma corp